hypogonadism

If you’re searching late at night about erectile dysfunction, low testosterone, libido, or fertility, you’re not alone—and those questions can be an important clue about your overall men’s wellness. In this episode of Baptist HealthTalk, host Dr. Anthony Gonzalez sits down with Dr. Justin...

In this episode, Dr. Kevin Chu and Justin Dubin discuss the recent updates to testosterone therapy labels, debunk myths about prostate cancer risks, and explore the future of testosterone treatment and regulation. They emphasize the importance of evidence-based practice and evolving medical...

In this episode, Dr. Rena Malik sits down with Dr. Martin Miner, Dr. Larry Lipshultz, and Dr. Tobias S. Kohler to unpack the myths and realities of testosterone therapy. The conversation covers who truly benefits from testosterone treatment, how guidelines are evolving, distinctions between...

JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss “Testosterone Therapy: Does New Evidence Warrant Broader Prescribing?”

Patiently waiting! Hubert W. Vesper, Ph.D How can laboratories and researchers ensure tests used in patient care and clinical research produces accurate and comparable results...

* Severe energy deficit, sleep disruption, and uncontrollable psychogenic stress suppress hypothalamic gonadotropin-releasing hormone and luteinizing hormone pulsatility, reduce testicular androgen production, and frequently increase sex hormone–binding globulin (SHBG), thereby...

But while Khera supports screening, he said he worries about inappropriate use of TRT. “I wouldn’t treat someone with TRT if they weren’t symptomatic” or had normal testosterone levels, says Khera, who helped publish seminal research on TRT and in 2025 led a U.S. Food and Drug Administration...

Standardized testosterone assays are available and improve accurate diagnosis of hypogonadism and ensure men who need treatment receive it. The use of a testosterone assay that has been certified by the CDC HoST program ensures that the assays have been standardized and “harmonized”; results...

* The particular threshold of 700 ng/dL chosen for this study demonstrated the greatest, most significant difference in CAG repeat length between the two groups. * In the cohort with complete follow-up data (n=75), patients whose testosterone levels superseded 700 ng/dL following therapy...

* Testosterone plays an important role in the maintenance of male skeleton. Most studies of testosterone therapy have demonstrated some degree of improvement in BMD * Based on elegant mechanistic studies (discussed below), the current thinking is that both testosterone and estradiol are...

In part one of this men’s health series, Dr. Eve Glazier and Jesse Mills, MD, health sciences clinical professor of urology and director of the Men’s Health Clinic at UCLA Health, examine how symptoms such as erectile dysfunction can offer important insights into overall health. They discuss why...

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, is joined by renowned male reproductive specialists Larry I. Lipshultz, MD, and Dolores J. Lamb, PhD, to discuss the science, clinical value, and future of the male infertility laboratory. Drawing on decades of collaboration in...

https://www.bcm.edu/healthcare/clinical-trials/h-56187 Description An Open-Label Multiple-Dose, 52-Week Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents (ages: 12 to <18 years) With Conditions Associated with Deficiency...

* Bhasin noted that, like fellow academics and endocrinologists, he has historically been cautious around testosterone therapy. “In the last 5 years or so, we’ve learned a lot more, and I’ve changed my position,” he said. “On one side, it’s very rigid, and on the other, it’s touted as the cure...

How do you protect your prostate, recognize the early signs of erectile dysfunction, and separate medical facts from internet myths? In this episode, Tom (he/him) sits down with Dr. Arthur Burnett (he/him), renowned Johns Hopkins urologist, researcher, and one of the pioneers behind the science...

https://www.linkedin.com/pulse/new-official-german-mens-health-portal-section-fcpfe Prof Dr med Dr hc Michael Zitzmann, MD. PhD, FRSM https://www.maennergesundheitsportal.de/themen/testosteronmangel-bei-maennern/

https://endo2026.endocrine.org/searchGlobal.asp Background Testosterone therapy is widely used for male hypogonadism but suppresses gonadotropins, reducing intratesticular testosterone and impairing spermatogenesis. These effects contribute to testicular atrophy, infertility, and increased...

* The findings support the Endocrine Society’s recommendation that direct IAs should not be used in clinical practice. https://endo2026.endocrine.org/fsPopup.asp?PresentationID=1845305&mode=presInfo Free testosterone (FT) is widely used in clinical diagnosis, management, and research of...

In this episode, Dr. Brandon and Dr. Morgentaler talk about the FDA's groundbreaking testosterone label changes, the evolving evidence on testosterone therapy and prostate cancer, and how quality of life should factor into treatment decisions for men with advanced disease. Time stamps...

2 Pathophysiology of Anabolic Steroid-Induced Hypogonadism 2.1 Central and Peripheral Mechanisms of HPG Axis Suppression 2.2 Mechanisms Contributing to Delayed Recovery 3 Overview of Post-Cycle Therapy Approaches 4 Pharmacology of Clomiphene Citrate 5 Clinical Evidence of Clomiphene...

Authors Gal Saffati, MD David E. Hinojosa-Gonzalez, MD Mohit Khera, MD, MBA, MH Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized...

Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer.

The FDA's proposed narrowing of the testosterone therapy prostate cancer contraindication to metastatic disease only reflects current clinical evidence, opening the door to testosterone therapy in appropriately selected men with treated localized prostate cancer or on active surveillance, with...

In this episode of AUANews Inside Tract, host Dr. Mark Edney speaks with Dr. Helen Burnie about the FDA’s proposed updates to testosterone therapy labeling and what they could mean for urologists, patients, and the broader field of men’s health. The discussion explores new evidence on...

More T is better they say LOL! Hate to burst your bubble but the reality of T physiology is thresholds, plateaus, and diminishing returns not a linear "more testosterone is better" dose-response. 36:25 Why Higher Testosterone Can Be So Addictive for Muscle Gain Chapters: 00:00 Why...

* TRT does not increase MACE risk in men with confirmed organic hypogonadism when titrated to physiological levels. Non-MACE signals warrant vigilance rather than contraindication. Metabolic optimisation should precede TRT in functional hypogonadism. Individualised monitoring and careful patient...

In this episode, Dr. Brandon and Dr. Morgentaler talk about navigating sexual differences in relationships, the latest evidence supporting testosterone therapy after prostate cancer treatment, and practical ways couples can rebuild intimacy and sexual confidence during recovery. 00:00 –...

* The program will launch in July 2026 and will initially be available in 37 states. * Life MD’s platform is designed to remove those barriers by combining clinically appropriate virtual evaluation, lab-based diagnosis, ongoing clinical support, and access to home delivery of an FDA-approved...

https://mariuspharma.com/news/marius-pharmaceuticals-applauds-fdas-proposed-testosterone-labeling-updates-as-a-turning-point-for-mens-health/ The FDA’s second major labeling update in 16 months — after its February 2025 removal of the cardiovascular boxed warning — marks a historic...

In conclusion, men with lower testosterone concentrations had higher risk of cancer death, and men with mid-range SHBG or luteinising hormone concentrations had lower risk. Low testosterone concentrations were associated with risk of any fatal or non-fatal incident cancer. Men with lower SHBG or...